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ABSTRACT 
The present study was aimed at developing and exploring the use of Angiopep-2 anchored PEGylated Poly propyleneimine (PPI) dendrimers 
for targeted delivery of paclitaxel to the brain glioma. PPI dendrimers were synthesized and modified with PEG-2000 for surface 
neutralization. PEGylated PPI dendrimers were further conjugated with Angiopep-2 (ANG-PEG-PPP) for improved drug delivery across blood 
brain barrier (BBB) into the vicinity of brain glioma.  Ligand conjugated PPI dendrimers were loaded with Paclitaxel (PAPP) and characterized 
for size, percentage drug loading, cumulative drug release and cell line studies. Drug loading was found to be 57.42±0.8% while in vitro release 
profile depicted an initial burst release followed by zero order kinetics (46.8±0.8% in 24hr). MTT assay and cellular uptake studies on PAPP 
dendrimers demonstrated an enhanced antiproliferative activity against C6 glioma cells. Targeting potential of PAPP was evaluated using in 
vitro co culture model of BCECs and C6 glioma cells. Our study concludes, Angiopep-2 conjugated PEGylated PPI dendrimers as a promising 
nanocarrier for targeted delivery of paclitaxel to the brain glioma. 
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INTRODUCTION 
Human brain is the most delicate and protected organ of 
body surrounded by dense network of blood vessels and 
connective tissue membranes called meninges [1]. Several 
diseases and disorders like encephalitis, multiple sclerosis, 
neurological disorder, stroke and tumor may affect the 
normal functioning of brain. Brain glioma especially 
glioblastoma multiforme (GBM) a type of brain tumor is one 
of such serious diseases which adversely affects the brain’s 
anatomy and physiology [2,3]. GBM is most frequently 
encountered aggressive type of grade IV brain tumor, which 
has poor prognosis and high rate of recurrence making it a 
major reason behind cancer death in adults less than 35 
years of age. GBM cells easily diffuse from one site to the 
other nearby healthy tissues, posturing its complete 
eradication impossible using conventional chemotherapies 
or surgical method and thus tumor recurrence is more 
frequent [4,5]. Conventional drug delivery methods are 
incapable to deliver anticancer drugs effectively to the 
tumor as well as to migrating cells in brain however; they 
may often result in systemic side effects. The effectiveness 
of anticancer drugs is limited due to poor permeability of 
majority of drug molecules across the BBB either because of 
their larger size or due to low lipophilicity. Another problem 
in chemotherapy is maintaining a higher concentration of 
therapeutic agents at the tumor site and then preventing 
their spread into healthy tissue [6,7]. Thus to treat GBM 
effectively, limitations of conventional drug delivery 
methods should be overcome by novel drug delivery 
strategies. In the present era nanotechnology based drug 
delivery systems (NDDS) are increasingly applied in cancer 
therapy because of their site specific accumulation in tumor 
cells either by enhanced permeation and retention (EPR) 
effect or active targeting delivery [8-11].  
In the present study we have designed a novel nano-carrier 
that can carry drugs cross the BBB and then target the 
tumor without affecting normal brain and body cells. We 
have synthesized poly propyleneimine (PPI) dendrimers as 
drug delivery system and coated with PEG-2000 before 
loading paclitaxel a powerful anti-neoplastic agent against 
malignant glioma cells [12,13]. However, it is crucial for 
PEGylated PPI dendrimers to deliver drugs across the BBB 
and therefore our strategy for brain glioma targeting, 
mainly focused on receptor mediated endocytosis (RME). 
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GBM bearing brain express large number of receptors on 
the luminal endothelial plasma membranes, including the 
transferring receptor, the insulin receptor, endothelial 
growth factors receptor, and low-density lipoprotein 
receptor [14,15]. Out of this low-density lipoprotein 
receptor are extensively present on BBB as well as human 
glioma cells. This makes LRP as a potential targeted moiety 
for effective drug delivery to the glioma cells [16,17]. 
Angiopep-2, is reported as a ligand of LRP which possesses a 
high brain penetration and perfusion capability in mice [18]. 
Angiopep-2 can be used to enhance the drug delivery across 
BBB along the targeting of brain glioma. Thus in the present 
study we have conjugated angiopep-2 with PEGylated PPI 
dendrimers to deliver paclitaxel site specifically to the 
glioma cells. Paclitaxel (PTX), has been selected as model 
anti cancer for the treatment of brain glioblastoma. 
However its poor aqueous solubility and low therapeutic 
index make it suitable for the delivery through PEGylated 
PPI dendrimers [19,20]. 
2. MATERIALS AND METHODS 
2.1. Materials 
Ethylenediamine (EDA) and acrylonitrile (ACN) were 
purchased from CDH, India. Cellulose dialysis bag (MWCO 
12-14 KDa, Himedia, India), Fluorescein Isothiocyanate 
(FITC), MePEG2000 and Raney Nickel were obtained from 
Merck, India. Triethylamine, dioxan, succinic anhydride, N, 
N dicyclohexyl carbodiimide (DCC), 4 dimethyl amino 
pyridine were procured from sd-fine chemicals, India. 
Angiopep-2 was purchased from Shanghai GenePharma Co., 
Ltd. (Shanghai, China). Paclitaxel was a benevolent gift 
sample obtained from Panacea Biotech Ltd. (New Delhi). 
Penicillin, streptomycin mixture was purchased from Sigma, 
St. Louis, Missouri. Dulbecco’s Modified Eagle Medium 
(DMEM), fetal bovine serums (FBS) were procured from 
HiMedia, Mumbai, India. All other chemicals were of 
analytical grade and used without any further modification. 
2.2. Cell lines and culture conditions 
The BCECs and C6 glioma cells were procured from Centre 
for Cellular & Molecular Biology (CCMB) Pune. The cells 
were routinely cultured in DMEM containing 10% FBS 
supplemented with 0.25% (w/v) trypsin, 1% penicillin 
streptomycin mixture. All the cells were cultured in 
incubators maintained at 37oC under a humidified 
atmosphere containing 5% CO2. All experiments were 
performed on cells in the logarithmic phase of growth. 
2.3. Synthesis of dual targeted delivery system 
2.3.1. Synthesis of 4.0G EDA-PPI core dendrimers  
The half generation EDA-dendrimer-(CN)4n (where n is 
generation of reaction or reaction cycle) was synthesized by 
double Michael addiction reaction between ACN (2.5 molar 
times per terminal NH2 group of core amine moiety) and 
aqueous solution of EDA. After the initial exothermic phase, the 
reaction mixture was heated at 80ºC for 1hr to complete the 
addiction reaction. The excess of acrylonitrile was then 
removed by vacuum distillation (16 mbar, bath temperature 
40ºC). The full generation EDA-dendrimer-(NH2)4n was 
obtained by hydrogenation of half generation dendrimers in 
methanol at 40 atm hydrogen pressures and 70ºC for 1hr with 
Reney Nickel. PPI dendrimers up to 4.0G were prepared by 
repetition of all the above steps consecutively, with increasing 
quantity of ACN [21-23]. 
2.3.2. PEGylation of 4.0G PPI Dendrimers (PEG-PPI) 
PEG2000 (8 g, 8 mmol), succinic anhydride (500 mg, 10 
mmol), 4 dimethyl amino pyridine (488 mg, 8 mmol) and 
triethylamine (404 mg, 8 mmol) were dissolved in dioxane 
and stirred over night at room temperature. Dioxane was 
completely removed from the resulting solution and residue 
was dissolved in dichloromethane, filtered and 
concentrated. Resultant PEGCOOH2000 was precipitated 
out with ether and dried in oven to remove final traces of 
solvents. To a solution of 4.0G PPI dendrimer (0.01mmol) in 
dimethyl sulfoxide (DMSO) (10 ml), PEGCOOH2000 
(0.32mmol) in DMSO (10 ml) and DCC (0.32 mmol) in DMSO 
(10 ml) were added and stirred at room temperature for 5 
days. The product was precipitated by addition of water, 
filtered and dialyzed (MWCO 12-14 Kda, Himedia, India) 
against double distilled water for 24 hr to remove free 
PEGCOOH2000, DCC and partially PEGylated dendrimers 
followed by lyophilization (Heto drywinner, Germany) [24-
28]. 
2.3.3. Preparation of angiopep-2 conjugated PEGylated 
PPI dendrimers (ANG-PEG-PPI) 
ANG-PEG-PPI was prepared by reacting activated PEG-PPI 
dendrimers with Angiopep-2 in PBS (pH 7.4) for 8 hr under 
nitrogen flow at room temperature. The outer groups of 
activated PEG-PPI dendrimers were specifically reacted 
with the thiol groups of Angiopep-2. The reaction mixture 
was then centrifuged at 12,000 rpm for 60 min at 4oC and 
dialyzed (MWCO 12-14Kda) against PBS buffer (pH 7.4) for 
24 hr to remove free ANG and PEG-PPI. Residue was re-
suspended in PBS (pH 7.4) and kept at 4oC for further use 
[29].  
2.3.4. PTX loading in ANG-PEG-PPI (PAPP) 
Known molar concentration (1:1) of ANG-PEG-PPI was 
dissolved in methanol and mixed with methanolic solution 
of PTX. The mixed solutions were incubated with slow 
magnetic stirring (50 rpm) using teflon beads for 24 hr. This 
solution was twice dialyzed in cellulose dialysis bag (MWCO 
1000 Da Sigma, Germany) against double distilled water to 
remove free drug. Concentration of free drug was estimated 
spectrophotometrically (λmax 227 nm) (UV-1601, Shimadzu, 
Japan) to determine indirectly the amount of drug loaded 
within the system. The dialyzed formulations were 
lyophilized and used for further characterization. FITC 
loaded ANG-PEG-PPI dendrimers (FAPP) were prepared 
similar to the preparation of PTX loaded formulation [30].  
2.5. Characterization of PAPP dendrimers 
2.5.1. Morphological studies of the PAPP dendrimers 
Transmission electron microscopy (TEM) was performed to 
investigate particle size and morphology of dendrimer 
formulation. The TEM studies were carried out using 3mm 
Forman (10.5% plastic powder in amyl acetate) coated 
copper grid (300 mesh) at 60 KV using negative staining by 
2% phosphotungstic acid (PTA) for whole generation of 
dendrimers at 150,000X magnification on Philips CM-10 
TEM and Fei-Philips Morayagni 268D with digital TEM 
image analysis system. 
2.5.2. FTIR, 1H NMR and Mass spectroscopies  
4.0G PPI, PEG-PPI and ANG-PEG-PPI dendrimer were 
lyophilized and separately analyzed by FTIR (Perkin Elmer-
Spectrum RX-I, PU, Chandigarh), 1H NMR at 300 Hz (Avance-
II (Bruker, Germany) and Mass spectroscopy by MALDI-TOF 
(Micromass Tof-Spec 2E instrument, USA). 
2.5.3. Percentage drug loading 
Percentage Drug-loading (DL%) was calculated by the 
following equation 
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2.5.4. In vitro drug release 
PAPP dendrimer formulation (containing 5 mg of PTX) was 
dispersed in 2 ml of PBS (pH 7.4), and transferred into 
dialysis bag (MWCO 2000 Da). The dialysis bags was end-
sealed and submerged into 100 ml of PBS (pH 7.4) with 
continuous stirring under sink condition at 37oC in dark. At 
definite time intervals, 1 ml of solution was withdrawn and 
replaced with an equal volume of fresh medium. The 
amount of PTX release was analyzed spectrophotometrically 
at λmax 227 nm [31-33].  
2.6. In vitro cytotoxicity assay 
Cytotoxicity studies were carried out as per the standard 
procedure for methylthiazole tetrazolium (MTT) assay. C6 
glioma cells were used to evaluate the cytotoxicity of PAPP 
dendrimers. C6 glioma cells were seeded in 96-well plates 
with a density of 10,000 cells/well, and allowed to adhere 
for 24 hr prior to assay. Then free PTX and PAPP 
dendrimers were added to the plates at a series of PTX 
concentrations from 0 to 10 µM. Blank ANG-PEG-PPI 
without PTX was used to test the cytotoxicity of carrier. 
After each treatment, the cells were incubated with 0.5 
mg/ml MTT in DMEM for 4 hr in dark and then mixed with 
dimethyl sulfoxide after the supernatant was removed. The 
absorbance at 570 nm was detected using the microplate 
reader (Synergy TM2, BIO-TEK Instruments Inc. USA). Cell 
viability was determined by the percentage of OD value of 
the study group over the control group [34,35]. 
2.7. Cellular uptake of FAPP dendrimers 
C6 glioma cells were placed on glass cover slips that were 
placed in 6-well plates. After 24 hr, cells were preincubated 
in DMEM for 30 min, and then treated with FAPP 
dendrimers (containing 10µg/ml FITC) and FITC loaded 
PEGylated PPI dendrimers (FPPD) in DMEM for 2 hr. Cells 
on coverslips were washed with PBS (pH 7.4). The samples 
were subjected to observe with fluorescent microscope 
(Leica DMI 4000B, Germany) [36]. 
In vitro drug targeting study  
Drug targeting effect of PAPP dendrimers was studied in co-
culture model of BCECs and C6 glioma cells. BCECs 
incubated in transwell for 4 days subsequently transferred 
into another 24 well culture plate containing previously 
cultured C6 glioma cells and incubated further for 24 hr. Co-
culture model was exposed to serum free DMEM and 
Angiopep-2 for 30 min before treating with free PTX, PTX 
loaded PPI dendrimers (PPD), PTX loaded PEGylated PPI 
dendrimers (PPPD) and PAPP dendrimers. After 8hr of 
incubation period transwell was removed and C6 glioma 
cells were further cultured to determine the cell survival 
using MTT assay [37]. 
3. RESULTS  
3.1. Synthesis and characterization of ANG-PEG-PPI 
(4.0G) dendrimer 
In the present study 4.0G PPI dendrimers were synthesized 
according to the procedure reported by De Brabender-Van 
Den Berg and Meijer using EDA as initiator core and ACN as 
branching units [21]. Synthesis of 0.5G PPI was also 
confirmed by IR peaks, mainly of nitrile at 2249 cm-1. All the 
nitrile terminal of 0.5G PPI converted into primary amine in 
1.0G PPI and further confirmed by IR peak at 3432 cm-1 for 
primary amine (N—H stretch). Similarly synthesis of 4.0G 
PPI dendrimer was confirmed by IR peaks at C-C bend 
(1109 cm-1); C-N stretch (1301cm-1); C-H bend (1411 cm-1, 
1465 cm-1); N-H deflection of amine (1667 cm-1) and 
primary amine at 3400 cm-1 (N-H stretch). Important shifts 
in NMR spectrum of 4.0G dendrimer at 3.24–3.86 ppm 
confirmed the presence of terminal –CH2NH2 groups while 
Mass spectrum confirmed 3527 Da molecular weight of 4.0G 
PPI dendrimer. PEGylation of 4.0G PPI dendrimers was also 
confirmed by FTIR and NMR spectra. Characteristic peak of 
secondary amide stretch at 3397.7cm-1, C-H stretch at 
2972.0 cm-1 and C=O stretch near 1653.6 cm-1 confirmed the 
PEGylation of the amine terminated dendrimers. NMR 
spectrum shown the shift of CO-NH bond at 7.41ppm and 
CH2-CH2-O bond at 3.49, 3.47 ppm. This is due to the 
presence of amide and ether linkages in PEGylated 
dendrimers. 
3.2. Characterization of PTX loaded ANG-PEG-PPI 
dendrimer 
TEM photographs of PTX loaded ANG-PEG-PPI dendrimers 
displayed the spherical shape of dendrimers with average 
particle size of 47±0.20 nm (Figure 1). Mass spectroscopy 
and 1H NMR studies confirmed the conjugation of ANG to 
PEG-PPI dendrimers. Percentage drug loading of PTX was 
found to be 57±0.8% which was higher than the 40±0.6% 
drug loading in plain 4.0G PPI dendrimers. Increased drug 
loading may be due to entrapment of PTX in dendrimer 
scaffold as well as in PEG network. In vitro cumulative 
release profile of PTX from drug loaded dendrimer 
formulations shown in Figure 2. PTX release from PEG-PPI 
dendrimers (PPPD) and ANG-PEG-PPI (PAPP) dendrimers 
was found to be 46.4±0.8% and 38.6±0.2% in 24hr 
respectively. However both formulation shown an initial 
burst release followed by zero order release profile. 
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 Figure 1: TEM images of ANG-PEG-PPI dendrimers 
 
Figure 2: Cumulative PTX release from PTX loaded PEG-PPI dendrimers and PTX loaded ANG-PEG-PPI dendrimers 
(n=3) 
3.3. Cytotoxicity assay 
The cytotoxicity of free drug PTX and PTX loaded ANG-PEG-
PPI dendrimer was studied on C6 glioma cells against blank 
ANG-PEG-PPI dendrimers. Blank dendrimer formulation 
exhibited low toxicity and good biocompatibility at 
concentrations (<0.1µg/ml) comparative to the free PTX 
and PAPP dendrimer. However at higher concentrations 
blank dendrimers elicited cell inhibition due to its own 
cytotoxic nature. At lower concentrations (<0.01µg/ml) of 
PAPP dendrimer, C6 glioma Cells viability was near 75% 
which drastically fall at higher concentrations. PAPP 
exhibited highest inhibitory effect of cell proliferation 
comparative to other formulations. The IC50 value of PAPP 
(0.088±0.002 µg/ml) was 3.2 times lower than the free PTX 
(0.282±0.06 µg/ml) indicating higher antiproliferative 
activity of PAPP dendrimers (Figure 3). 
 
 
Figure 3: In vitro cytotoxicity of various formulations of PTX against C6 cells (n=3)  
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3.4. Cellular uptake of FAPP dendrimers 
C6 glioma cells exhibited more intense green fluorescence 
when incubated with FAPP dendrimers comparative to 
FPPD dendrimer formulation indicating the higher cellular 
uptake of FAPP dendrimers. Higher fluorescence intensity of 
FAPP dendrimers corresponds to the presence of Angiopep-
2 on the dendrimer surface and considered as the result of 
ligand receptor mediated cellular uptake of FAPP 
dendrimers. FPPD dendrimers uptake by the C6 glioma cell 
was very limited. However on increasing the exposure time 
an increased fluorescence was observed. 
3.5 In vitro drug targeting study  
In order to determine the targeting efficiency of FAPP 
dendrimers co-culture model of BCECs and C6 glioma cells 
was developed. The percentage cell viability of C6 glioma 
cells treated with PAPP dendrimer formulation was found to 
be least than that of free PTX, PTX loaded PPI dendrimers, 
PTX loaded PEGylated PPI dendrimers (Figure 4). The cell 
growth inhibitory activity of PAPP dendrimers was 
significantly reduced when C6 glioma cells were pretreated 
with angiopep-2 before incubating with PAPP dendrimers. 
Competitive binding of ligand with receptor may be 
responsible for this. It demonstrated the potential of 
angiopep-2 conjugated with PEGylated PPI dendrimers to 
deliver drugs across the BBB targeting specifically to C6 
glioma cells. 
   
 
Figure 4: Targeting effect: cell viability of free PTX, PTX-PPI, PTX-PEG-PPI, PTX-ANG-PEG-PPI and PTX-ANG-PEG-PPI 
+Angiopep-2 against Co culture of BCECs and C6 glioma cells (n=3). 
 
4. DISCUSSION 
The success of chemotherapy in GBM treatment is largely 
depends on the specific drug delivery to the GBM cell 
vicinity leaving normal cells unaffected. However 
conventional drug delivery strategies has limited success 
due to their nonspecific drug delivery and greater side 
effects. Another big obstacle in GBM chemotherapy is BBB 
which restrict the adequate amount of drug delivery to the 
brain GBM. Hence a novel drug delivery strategy that could 
deliver significant amount of anticancer drug across the BBB 
with reduced side effects and improved patient’s survival 
time is highly required. PPI dendrimers is considered one of 
the promising nanocarrier which are globular, 
hyperbranched, biocompatible systems with low toxicity 
profile. However highly positive charge at surface 
dendrimers can be reduced by surface modification using 
PEG molecules. These long circulating PEGylated PPI 
dendrimers alone are incapable of drug targeting and thus 
required to be targeted using ligand receptor interaction. It 
is reported that LRP receptors are overexpressed on BBB as 
well as GBM cells which show competitive affinity to bind 
with different lipoproteins.  Angiopep-2 a novel peptide 
containing 19 amino acids possesses a higher LRP affinity to 
cross BBB than other proteins.  
In the present study we have developed Angiopep-2 
conjugated PEGylated PPI dendrimers as drug carrier for 
GBM specific drug delivery. In ANG-PEG-PPI dendrimers, 
Angiopep-2 was linked to PPI dendrimers using bifunctional 
PEG. PPI dendrimers were characterized by FTIR, NMR and 
Mass spectroscopies for confirming the synthesis and 
structural uniformity. The particle size of ANG-PEG-PPI 
dendrimer was found to be less than 100 nm, which was 
optimum for dendrimer endocytosis by brain capillary 
endothelial cells. Higher drug payload and controlled 
release profile of PTX loaded ANG-PEG-PPI dendrimers was 
further proved it’s superiority in drug delivery.  
PTX loaded ANG-PEG-PPI dendrimers has shown a better 
anti-glioma effect than PTX alone, which was proven by 
enhanced C6 glioma cell inhibition. The MTT assay 
demonstrated that PAPP dendrimer formulation resulted in 
greater cytotoxicity effects in C6 glioma cells. Reduced IC50 
value for PAPP dendrimers comparative to free PTX, 
suggested its better antiproliferative activity against C6 
glioma cells. Ligand receptor interaction understood to be 
responsible for increased endocytosis of PAPP dendrimers. 
Targeting efficiency of the PAPP dendrimer formulation was 
evaluated in BCECs and C6 glioma cells co-culture. The 
inhibitory effects on C6 cells were significantly enhanced 
when Angiopep-2 conjugated to PTX-loaded PEG-PPI 
dendrimers. However when the co-culture was exposed to 
the angiopep-2 before treating with PAPP, significant fall in 
cell inhibitory activity was observed. This strongly indicated 
the targeting efficacy of PTX loaded ANG-PEG-PPI 
dendrimers. 
5. CONCLUSIONS 
PPI dendrimers are well established monodisperse 
nanocarrier for drug delivery. However highly positive 
surface charge due to presence of amine group restrict their 
biomedical applications. In the present study we have 
PEGylated the PPI dendrimers rendering them neutral and 
Parashar et al                                                                                                        Journal of Drug Delivery & Therapeutics. 2018; 8(6-A):74-79  
ISSN: 2250-1177                                                                                  [79]                                                                                 CODEN (USA): JDDTAO 
biocompatible. Further modification with Angiopep-2 
improved their BBB crossing activity along with the site 
specific drug delivery to the brain tumor. Physical 
characterization for size, structural integrity, drug loading 
capacity and in vitro cell line studies for increased 
cytotoxicity, cellular uptake and targeting confirmed its 
superiority over the free paclitaxel drug. Hence targeting 
potential of Angiopep-2 conjugated PEGylated PPI 
dendrimers across the BBB and in the vicinity of tumor can 
be concluded by the present study. 
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